Nuclear localized Akt enhances breast cancer stem-like cells through counter-regulation of p21Waf1/Cip1 and p27kip1

Cell Cycle

Volumn 14, Issue 13, 2015, Pages 2109-2120

  Jain, Mayur Vilas ^a   Jangamreddy, Jaganmohan R ^a   Grabarek, Jerzy ^b   Schweizer, Frank ^c   Klonisch, Thomas ^c   Cieślarpobuda, Artur ^a,d   Łos, Marek J ^a,b,e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF MANITOBA   (Canada)

^d SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Akt NLS; Cancer stem like cells; mTOR; PI3K; Stemness

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; CYCLIN A1; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; PROTEIN KINASE B; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRICIRIBINE; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER STEM CELL; CELL COMPARTMENTALIZATION; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL NUCLEUS; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CLONOGENESIS; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; NUCLEAR REPROGRAMMING; PHENOTYPE; PROTEIN EXPRESSION; UPREGULATION; BREAST TUMOR; CHEMISTRY; FEMALE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84943760673     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1041692     Document Type: Article

References (49)

1. Farahani E, PatraHK, Jangamreddy JR, Rashedi I, KawalecM, Rao Pariti RK, Batakis P, Wiechec E. Cell adhesion molecules and their relation to (cancer) cell stemness. Carcinogenesis 2014; 35: 747-59; PMID: 24531939; http://dx. doi. org/10. 1093/carcin/bgu045.
2. Wasik AM, Grabarek J, Pantovic A, Cieslar-Pobuda A, Asgari HR, Bundgaard-Nielsen C, Rafat M, Dixon IM, Ghavami S, Los MJ. Reprogramming and carcinogenesis-parallels and distinctions. Intl Rev Cell Mol Biol 2014; 308: 167-203; PMID: 24411172; http://dx. doi. org/10. 1016/B978-0-12-800097-7. 00005-1.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8; PMID: 12629218; http://dx. doi. org/10. 1073/pnas. 0530291100.
4. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol 2004; 5: 738-43; PMID: 15170211; http://dx. doi. org/10. 1038/ni1080.
5. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401; PMID: 15549107; http://dx. doi. org/10. 1038/nature03128.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10; PMID: 17122772; http://dx. doi. org/10. 1038/nature05372.
7. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7; PMID: 17283135; http://dx. doi. org/10. 1158/0008-5472. CAN-06-2030.
8. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973-8; PMID: 17210912; http://dx. doi. org/10. 1073/pnas. 0610117104.
9. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51; PMID: 16322242; http://dx. doi. org/10. 1158/0008-5472. CAN-05-2018.
10. Hombach-Klonisch S, Paranjothy T, Wiechec E, Pocar P, Mustafa T, Seifert A, Zahl C, Gerlach KL, Biermann K, Steger K, et al. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Archivum Immunol Ther Exp 2008; 56: 165-80; PMID: 18512024; http://dx. doi. org/10. 1007/s00005-008-0023-4.
11. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, Los M. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 2008; 14: 450-60; PMID: 18775674; http://dx. doi. org/10. 1016/j. molmed. 2008. 08. 003.
12. Jangamreddy JR, Ghavami S, Grabarek J, Kratz G, Wiechec E, Fredriksson BA, Rao Pariti RK, Cieslar-Pobuda A, Panigrahi S, Los MJ. Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: differences between primary and cancer cells. Biochim Biophy Acta 2013; 1833: 2057-69; PMID: 23639289; http://dx. doi. org/10. 1016/j. bbamcr. 2013. 04. 011.
13. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65: 3145-67; PMID: 18581055; http://dx. doi. org/10. 1007/s00018-008-8111-5.
14. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-510; PMID: 18794884; http://dx. doi. org/10. 1038/onc. 2008. 245.
15. Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 2013; 1830: 2481-95; PMID: 23196196; http://dx. doi. org/10. 1016/j. bbagen. 2012. 11. 008.
16. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. HER-2/neu blocks tumor necrosis factorinduced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000; 275: 8027-31; PMID: 10713122; http://dx. doi. org/10. 1074/jbc. 275. 11. 8027.
17. Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, Jalaludin B, Segelov E. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 2004; 23: 617-28; PMID: 14724591; http://dx. doi. org/10. 1038/sj. onc. 1207059.
18. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Ann Rev Cell Dev Biol 2001; 17: 615-75; PMID: 11687500; http://dx. doi. org/10. 1146/annurev. cellbio. 17. 1. 615.
19. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-54; PMID: 10579926; http://dx. doi. org/10. 1006/excr. 1999. 4701.
20. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Ann Rev Biochem 1998; 67: 481-507; PMID: 9759495; http://dx. doi. org/10. 1146/annurev. biochem. 67. 1. 481.
21. Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev 2000; 14: 1027-47; PMID: 10809663.
22. Ye K. PIKE/nuclear PI 3-kinase signaling in preventing programmed cell death. J Cell Biochem 2005; 96: 463-72; PMID: 16088938; http://dx. doi. org/10. 1002/jcb. 20549.
23. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Fala F, Cocco L. Intranuclear 30-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 2006; 18: 1101-7; PMID: 16516442; http://dx. doi. org/10. 1016/j. cellsig. 2006. 01. 011.
24. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007; 26: 1338-45; PMID: 17322919; http://dx. doi. org/10. 1038/sj. onc. 1210202.
25. Maddika S, Panigrahi S, Wiechec E, Wesselborg S, Fischer U, Schulze-Osthoff K, Los M. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol Cell Biol 2009; 29: 1235-48; PMID: 19103742; http://dx. doi. org/10. 1128/MCB. 00668-08.
26. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15: 177-82; PMID: 15209377; http://dx. doi. org/10. 1016/j. semcdb. 2004. 01. 002.
27. Los M, Maddika S, Erb B, Schulze-Osthoff K. Switching Akt: from survival signaling to deadly response. BioEssays 2009; 31: 492-5; PMID: 19319914; http://dx. doi. org/10. 1002/bies. 200900005.
28. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9: 667-76; PMID: 15505410; http://dx. doi. org/10. 1023/B: APPT. 0000045801. 15585. dd.
29. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-60; PMID: 12244302; http://dx. doi. org/10. 1038/nm761.
30. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3: 245-52; PMID: 11231573; http://dx. doi. org/10. 1038/35060032.
31. Watanabe S, Umehara H, Murayama K, Okabe M, Kimura T, Nakano T. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene 2006; 25: 2697-707; PMID: 16407845; http://dx. doi. org/10. 1038/sj. onc. 1209307.
32. Fischer KM, Din S, Gude N, Konstandin MH, Wu W, Quijada P, Sussman MA. Cardiac progenitor cell commitment is inhibited by nuclear Akt expression. Circ Res 2011; 108: 960-70; PMID: 21350213; http://dx. doi. org/10. 1161/CIRCRESAHA. 110. 237156.
33. Gong J, Traganos F, Darzynkiewicz Z. Growth imbalance and altered expression of cyclins B1, A, E, and D3 in MOLT-4 cells synchronized in the cell cycle by inhibitors of DNA replication. Cell Growth Differ 1995; 6: 1485-93.
34. Cieslar-Pobuda A, Back M, Magnusson K, Jain MV, Rafat M, Ghavami S, Nilsson KP, Los MJ. Cell type related differences in staining with pentameric thiophene derivatives. Cytometry Part A 2014; 85: 628-35; PMID: 24500794; http://dx. doi. org/10. 1002/cyto. a. 22437.
35. Magnusson K, Appelqvist H, Ciéslar-Pobuda A, Wigenius J, Karlsson Tos MJ, Kágedal B, Jonasson J, Nilsson KPR. Differential vital staining of normal and transformed cells by an anionic conjugated polyelectrolyte. Cytometry Part A 2015; 87(3): 262-72: (#14-120, provisionally accepted); PMID: 25605326.
36. Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S, Schaefer E, Walsh K, Rosenzweig A, Torella D, et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res 2004; 94: 884-91; PMID: 14988230; http://dx. doi. org/10. 1161/01. RES. 0000124394. 01180. BE.
37. Bijur GN, Jope RS. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J Neurochem 2003; 87: 1427-35; PMID: 14713298; http://dx. doi. org/10. 1046/j. 1471-4159. 2003. 02113. x.
38. Lin Y, Yang Y, Li W, Chen Q, Li J, Pan X, Zhou L, Liu C, Chen C, He J, et al. Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell 2012; 48: 627-40; PMID: 23041284; http://dx. doi. org/10. 1016/j. molcel. 2012. 08. 030.
39. Peltier J, Conway A, Keung AJ, Schaffer DV. Akt increases sox2 expression in adult hippocampal neural progenitor cells, but increased sox2 does not promote proliferation. Stem Cell Dev 2011; 20: 1153-61; PMID: 21028992; http://dx. doi. org/10. 1089/scd. 2010. 0130.
40. Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 2008; 105: 6584-9; PMID: 18451027; http://dx. doi. org/10. 1073/pnas. 0802785105.
41. Evangelisti C, Ricci F, Tazzari P, Chiarini F, Battistelli M, Falcieri E, Ognibene A, Pagliaro P, Cocco L, McCubrey JA, et al. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol 2011; 226: 822-31; PMID: 20857426; http://dx. doi. org/10. 1002/jcp. 22407.
42. Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, Los MJ. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp 2013; 61: 43-58; PMID: 23229678; http://dx. doi. org/10. 1007/s00005-012-0205-y.
43. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, Christoffersson J, Chaabane W, Moghadam AR, Kashani HH, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014; 112: 24-49; PMID: 24211851; http://dx. doi. org/10. 1016/j. pneurobio. 2013. 10. 004.
44. Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, et al. Subcellular localization of activated AKT in estrogen receptor-and progesterone receptorexpressing breast cancers: potential clinical implications. Am J Pathol 2010; 176: 2139-49; PMID: 20228224; http://dx. doi. org/10. 2353/ajpath. 2010. 090477.
45. Wiechec E. Implications of genomic instability in the diagnosis and treatment of breast cancer. Expert Rev Mol Diagn 2011; 11: 445-53; PMID: 21545260; http://dx. doi. org/10. 1586/erm. 11. 21.
46. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11; PMID: 11689955; http://dx. doi. org/10. 1038/35102167.
47. Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006; 16: 60-4; PMID: 16377171; http://dx. doi. org/10. 1016/j. gde. 2005. 12. 008.
48. Tan S, Ng Y, James DE. Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochem J 2011; 435: 539-44; PMID: 21348862; http://dx. doi. org/10. 1042/BJ20110040.
49. Chan CK, Jans DA. Using nuclear targeting signals to enhance non-viral gene transfer. Immunol Cell Biol 2002; 80: 119-30; PMID: 11940112; http://dx. doi. org/10. 1046/j. 1440-1711. 2002. 01061. x.